Health Care • Biotechnology: Pharmaceutical Preparations
$32.89 ▼ -1.07
(-3.15%)
MKT CAP: $3.17B • VOL: 1.62M
52W L $27 52W H $43
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$28
MEDIAN
$37
MEAN
$37
HIGH
$45
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE IDYA TAPE
IDYA // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $39.80 | $37.82 | 2025-02-14 | $29.93 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $41.44 | $38.81 | 2025-02-06 | $30.92 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $37.49 | $36.18 | 2025-01-29 | $31.57 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $33.55 | — | 2025-01-17 | $32.23 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $28.94 | $31.25 | 2025-01-09 | $29.27 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $39.14 | $34.21 | 2024-12-18 | $28.61 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $31.90 | $33.22 | 2024-12-04 | $30.59 | -4.3% | 48% | C |